- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03951415
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)
Study Overview
Status
Intervention / Treatment
Detailed Description
The prognosis of recurrent or persistent endometrial carcinoma not amenable to local therapy is poor. First line therapy exists of platinum-based chemotherapy or hormonal therapy. No standard subsequent-line therapy has been described.The combination of Poly(ADP-ribose) polymerases (PARP) inhibition and Programmed death-ligand 1 (PD-L1) blocking has great potential in the treatment of recurrent endometrial cancer. The DOMEC trial is designed to investigate this treatment combination among all molecular subgroups.
The DOMEC trial is designed as a DGOG, prospective, multi-center, phase II study for 55 patients with advanced (recurrent, refractory or metastatic) endometrial cancer, including carcinosarcoma of the uterus. Patients must have had one prior platinum-based chemotherapeutic regimen or not be able/willing to get chemotherapy. The aim is to investigate the efficacy of the combination therapy of olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks in terms of progression free survival. Secondary objectives are to investigate objective response rate, overall survival, safety and predictive biomarkers.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- NKI-AVL
-
Amsterdam, Netherlands, 1105 AZ
- Amsterdam UMC, AMC
-
Groningen, Netherlands
- Universitair Medisch Centrum Groningen
-
Leiden, Netherlands, 2300RC
- Leiden University Medical Center
-
Maastricht, Netherlands
- Academisch Ziekenhuis Maastricht
-
Nijmegen, Netherlands
- RadboudMC
-
Rotterdam, Netherlands
- Erasmus MC
-
Utrecht, Netherlands
- Universitair Medisch Centrum Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Written informed consent
- Age > 18 years old
- Histologically confirmed diagnosis of endometrial cancer or carcinosarcoma of the endometrium.
- Metastatic disease or locally advanced tumor not amenable to local therapy.
- Documented progressive disease before enrolment.
- Measurable lesions outside irradiated field or progressive measurable lesions in irradiated area
- Not eligible for hormonal therapy (because of negative hormone receptor/poor differentiation, or after failure of hormonal therapy).
- Previous failure of chemotherapy, or refusal to undergo chemotherapy or chemo-naive patients not suitable for chemotherapy.
- WHO performance 0-1
Adequate organ system function as measured within 28 days prior to administration of study treatment, as defined below:
- Haemoglobin ≥ 10.0 g/dL, with no blood transfusion in the past 28 days.
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (not applicable to Gilbert's syndrome)
- Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x ULN unless liver metastases are present in which case they must be ≤ 5x ULN
- Patients must have creatinine clearance estimated of ≥51 mL/min estimated using the Cockcroft-Gault equation or 24 hr urine clearance.
- Life expectancy of at least 16 weeks.
- Measurable disease as defined by RECIST 1.1 criteria
- Able to swallow and retain oral medication.
- A female is eligible to enter and participate in this study if there is:
Exclusion criteria:
- Participation in another clinical study with an investigational product during the last month or previous enrolment in the present study.
- Any previous treatment with PARP inhibitor, including olaparib and/or any previous treatment with a PD1 or PD-L1 inhibitor
- History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of investigational product and of low potential risk for recurrence or adequately treated non-melanoma skin cancer, lentigo maligna or carcinoma in situ.
- History of leptomeningeal carcinomatosis, symptomatic uncontrolled brain metastases (≤2mg/ day corticosteroids started ≥4 weeks prior to treatment is accepted) and spinal cord compression (unless received definitive treatment and clinically stable for 28 days) .
- Resting ECG with QTc > 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome
- Concomitant use of known strong or moderate CYP3A inhibitors and inducers.
- Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (except intranasal and inhaled corticosteroids or systemic prednisone ≤ 10 mg/day)
- Major surgery ≤2 weeks of starting study treatment
- History of active primary immunodeficiency
- Active or prior documented autoimmune or inflammatory disorders, with exception of: vitiligo or alopecia, hypothyroidism stable on hormone replacement, any chronic skin condition that does not require systemic therapy, celiac disease controlled by diet alone
- Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
- Active infection including tuberculosis, hepatitis B/C and HIV
- Patients with an expected or known hypersensitivity to olaparib or durvalumab or any of the excipients of the products.
- Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
- Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PARP inhibitor and Anti-PD-L1
olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
|
olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: 6 months
|
PFS will be counted from the date of registration until the first observation of radiological progressive disease according to RECIST 1.1 criteria or death due to any cause, whichever occurred first.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: 12 weeks
|
according to RECIST 1.1 criteria
|
12 weeks
|
Overall survival (OS)
Time Frame: Through study completion, up to 36 months
|
OS will be determined from the date of registration until death from any cause.
|
Through study completion, up to 36 months
|
Adverse events
Time Frame: Through study completion, up to 36 months
|
Assessed by NCI Common Terminology Criteria for adverse Events (CTCAE) version 5.0
|
Through study completion, up to 36 months
|
Predictive biomarkers in tumor biopsy
Time Frame: At baseline
|
MMRd/POLE, HR status, quantification of CD3,CD4,CD8,CD103,CD161,PD-1,LAG3,CTLA-4,NKG2A,GOXp3 positieve T cells, NK cells, percentage PD-L1 on myeloid cells/tumorcells, quantification of myeloid cell infiltration (CD68,CD14,CD33,CD163) in tumor biopsies.
|
At baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional HRD assay (optional)
Time Frame: At baseline
|
Extra biopsy
|
At baseline
|
Immunological effects of PARP-1 inhibition (optional)
Time Frame: Change From Baseline to 6 weeks and 12 weeks
|
Tests for T cell and APC functionality measured by the measurement of recall antigen responses and mixed lymphocyte cultures, respectively, the levels of regulatory T cells, activation markers on T cells and DC).
|
Change From Baseline to 6 weeks and 12 weeks
|
Predictive biomarkers for PD-L1 blocking in blood (optional)
Time Frame: Change From Baseline to 6 weeks and 12 weeks
|
e.g.
monocyticMDSC levels, DC levels, inhibitory marker expression, neutrophil-to-lymphocyte ratio, absolute lymphocyte count, T-cell reactivity during PD-L1 blocking, T-cell cytokine expression after SEB activation
|
Change From Baseline to 6 weeks and 12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Female
- Uterine Diseases
- Neoplasms
- Endometrial Neoplasms
- Uterine Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Olaparib
- Durvalumab
- Poly(ADP-ribose) Polymerase Inhibitors
Other Study ID Numbers
- DOMEC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Neoplasms
-
University of AarhusRecruitingUterine Cervical Neoplasm | Mass Screening | Uterine Cervical Disease | Uterine NeoplasmDenmark
-
GlaxoSmithKlineCompletedCervical Cancer | Neoplasms, Uterine Cervix
-
Huazhong University of Science and TechnologyChongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyUnknownCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Ding MaRecruitingUterine Cervical NeoplasmChina
-
Karolinska InstitutetKarolinska University Hospital; Regional Cancer Centre Stockholm GotlandEnrolling by invitationUterine Cervical CancerSweden
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingUterine Cervical CancerChina
-
Becton, Dickinson and CompanyTerminatedUterine Cervical NeoplasmUnited States, Canada
-
Hillel Yaffe Medical CenterUnknownUterine Neoplasms | Uterine Cervical NeoplasmIsrael
-
Centre Oscar LambretTerminatedUterine Cervical CancerFrance
Clinical Trials on PARP inhibitor and Anti-PD-L1
-
Peking Union Medical College HospitalRecruitingHepatocellular CarcinomaChina
-
Shanghai Chest HospitalRecruitingNon Small Cell Lung CancerChina
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Shanghai Zhongshan HospitalRecruiting
-
Melinta Therapeutics, Inc.Completed
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Zhongnan HospitalRecruiting
-
Tongji HospitalWuhan University; Sun Yat-sen University; Wuhan Union Hospital, ChinaSuspendedNon Small Cell Lung CancerChina
-
Xiaorong DongUnknown
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland